Navigation Links
FDA Accepts Noven's NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
Date:11/12/2012

MIAMI, FL and NEW YORK, NY, Nov. 12, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application (NDA) for low-dose mesylate salt of paroxetine (LDMP; 7.5 mg) for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause has been accepted for filing by the U.S. Food and Drug Administration (FDA). 

The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review. The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2013, which represents the goal date for the FDA to complete its review of the NDA.

In addition, the FDA advised Noven that the NDA for LDMP will be discussed at a meeting of the FDA's Reproductive Health Drugs Advisory Committee tentatively scheduled for March 4, 2013. 

Low-dose mesylate salt of paroxetine (LDMP) is an investigational oral nonhormonal therapy using 7.5 mg of paroxetine mesylate that was specifically developed for the treatment of vasomotor symptoms due to menopause. Noven submitted the LDMP NDA in August 2012. 

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven is committed to developing and offering products and technologies that meaningfully benefit patients, its customers and its industry partners. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., and serves as Hisamitsu's U.S. growth platform in prescription pharmaceuticals. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.hisamitsu.co.jp/english.

Contact

Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916

 


'/>"/>
SOURCE Noven Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2019)... ... 2019 , ... Intelligent.com, a trusted resource for online degree ... Healthcare Administration Degree Programs for 2020. The comprehensive research guide is based on ... is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. ...
(Date:12/6/2019)... N.C. (PRWEB) , ... December 06, 2019 , ... ... nonprofit funder of global MSA research, recently unveiled its bold new initiative to ... that strikes in the middle-years of life. , Infused by $3 million in ...
(Date:12/5/2019)... ... December 05, 2019 , ... nView, ... Maurice Rosenbaum to the role of Chief Product Officer. As the company expands ... changing dynamics of the behavioral health market into nView’s product and company growth ...
Breaking Medicine Technology:
(Date:12/9/2019)... , ... December 09, 2019 , ... ... companies, today announced new updates to the platform’s - - Change Management ... ability to identify, assess, and track the items impacted by change orders in ...
(Date:12/8/2019)... ... , ... Intelligent.com, a trusted resource for online degree rankings ... in Nursing (MSN) Degree Programs for 2020. The comprehensive research guide is based ... program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. ...
(Date:12/6/2019)... ... December 06, 2019 , ... Connecticut is home ... excellence in patient care. On December 12th, Hartford Business Journal will recognize eight ... Care Heroes Awards at the Hartford Marriott. , “We are fortunate to have ...
(Date:12/6/2019)... ... December 06, 2019 , ... Brain Sentinel, Inc. ... Maryland at the AES Annual Meeting. The symposium, “Fundamentals of Quantitative Surface Electromyography ... of quantitative sEMG analysis during ictal events;, 2. Review specific sEMG patterns of ...
(Date:12/5/2019)... ... 05, 2019 , ... HealthCareMandA.com is hosting an interesting and ... Thursday, December 12, 2019, at 1:00 PM ET. , Private equity firms and ... are scrambling to assemble regional platforms with enough scale and talent to attract ...
Breaking Medicine News(10 mins):